Chief Executive Officer and Chairman of the Board of Directors · CytomX Therapeutics, Inc. (CTMX)

D. Sean A. McCarthy

A named executive officer of CytomX Therapeutics in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,611,138

Salary $652,088Stock awards $1,048,950

FY2022: $3,013,606

1st of 3 named executive officers at CytomX Therapeutics by FY2023 total.

3 named officers on file for CytomX Therapeutics, FY2023

D. Sean A. McCarthy’s pay file — $29

  • 8 fiscal years of pay, line by line
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get D. Sean A. McCarthy’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

D. Sean A. McCarthy compensation by year

CytomX Therapeutics Summary Compensation Table · all 8 fiscal years held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$450,000$500,000$550,000$575,000$595,000$615,825$622,893$652,088
Bonus$0$0$0$0$0$0$0—
Stock awards$0$0$0$0$0$427,200$429,000$1,048,950
Option awards$2,213,348$2,284,886$4,514,280$2,862,180$1,892,850$2,931,890$1,559,160$533,201
Non-equity incentive$292,500$425,000$412,500$327,750$357,000$359,500$397,553$371,899
Pension and deferred compensation$0$0$0$0$0—$0—
All other$6,528$3,453$5,453$5,000$5,000$5,000$5,000$5,000
Total$2,962,376$3,213,339$5,482,233$3,769,930$2,849,850$4,339,415$3,013,606$2,611,138

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 4, 2024, accession 0001140361-24-017969, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-24-017969. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.

$3.0M
$3.2M
$5.5M
$3.8M
$2.8M
$4.3M
$3.0M
$2.6M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Insider transactions since the last proxy

20 Form 4 lines since the FY2023 proxy (filed April 4, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-17Sale10b5-1118,969$6.421,078,922
2026-02-02Grant or award—210,000$0.001,197,891
2026-02-02Grant or award derivative—980,000$0.00980,000
2025-11-06Sale10b5-1101,793$4.54987,891
2025-11-06Exercise or conversion10b5-1101,793$1.591,191,477
2025-11-06Exercise or conversion derivative10b5-1101,793$0.00348,207
2025-11-06Sale10b5-1101,793$4.541,089,684
2025-09-26Grant or award derivative—570,000$0.00570,000

The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CytomX Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
D. Sean A. McCarthy · this pageChief Executive Officer and Chairman of the Board of Directors$2,611,138
Marcia BelvinSenior Vice President, and Chief Scientific Officer$1,206,347
Jeff LandauSenior Vice President and Chief Business Officer$1,047,812

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

D. Sean A. McCarthy's compensation dossier · One-time report. No refunds.